Skip to content

Study · Not a test of the peptide alone · 2025

5 results

Clinical studies on anti-obesity medications in Arab countries.

AlOtaibi HF, Al Taib HN, AlMuhaidib S, Alshagrawi S, Almufarrih A, Alalmai O, Alnaserallah S, Alodah N, Alqahtani SA, Alhazzani W

Saudi medical journal1 May 2025Cited by 2 (Europe PMC)

PMID40335111 (opens in a new tab)PMCIDPMC12074045 (opens in a new tab)DOI10.15537/smj.2025.46.5.20250126 (opens in a new tab)PepBankPUB-40335111
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewOther

    In the searched scoping review of AOM studies in adult Arab populations, liraglutide was the most frequently studied GLP-1RA, appearing in 54.2% of studies; this is study coverage, not a patient response rate.

    In plain wordsIn reviewed adult Arab populations, liraglutide was the most studied GLP-1 medicine, appearing in 54.2% of studies.

    Peptide
    Liraglutide
    Outcome
    Not applicableFrequency of studies investigating liraglutide
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Whole body

    Measurements

    studies
    54.2%
    liraglutide

    Source sentences

    Summary
    Glucagon-like peptide-1 receptor agonists were investigated in 72.9% of the studies, with liraglutide being the most frequently studied agent (54.2%).
    2 context sentences
    Summary · context
    We carried out a comprehensive scoping review of primary studies examining the use of AOMs in adult Arab populations.
    Summary · context
    Five databases (Medline, Embase, Cochrane Library, Index Medicus for the Eastern Mediterranean Region, and e-Marefa) were searched for English-language publications up to October 2024.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewOther

    In the searched scoping review of AOM studies in adult Arab populations, total-body-weight outcome reporting occurred in 45.8% of studies; no liraglutide-specific efficacy estimate was stated.

    In plain wordsIn adult Arab AOM research, total-body-weight outcome reporting appeared in 45.8% of studies; this was not a liraglutide efficacy estimate.

    Peptide
    Liraglutide
    Outcome
    Not applicableTotal-body-weight outcome reporting across AOM studies
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Whole body

    Measurements

    Studies reporting outcome
    45.8%
    review-wide AOM studies; not a patient effect

    Source sentences

    Summary
    The most commonly reported efficacy outcomes included changes in total body weight (45.8%), body mass index (39.0%), and the proportion of weight loss (28.8%).
    3 context sentences
    Summary · context
    We carried out a comprehensive scoping review of primary studies examining the use of AOMs in adult Arab populations.
    Summary · context
    Five databases (Medline, Embase, Cochrane Library, Index Medicus for the Eastern Mediterranean Region, and e-Marefa) were searched for English-language publications up to October 2024.
    Summary · context
    Glucagon-like peptide-1 receptor agonists were investigated in 72.9% of the studies, with liraglutide being the most frequently studied agent (54.2%).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewOther

    In the searched scoping review of AOM studies in adult Arab populations, bmi-outcome reporting occurred in 39.0% of studies; no liraglutide-specific efficacy estimate was stated.

    In plain wordsIn adult Arab AOM research, bmi-outcome reporting appeared in 39.0% of studies; this was not a liraglutide efficacy estimate.

    Peptide
    Liraglutide
    Outcome
    Not applicableBMI-outcome reporting across AOM studies
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Whole body

    Measurements

    Studies reporting outcome
    39%
    review-wide AOM studies; not a patient effect

    Source sentences

    Summary
    The most commonly reported efficacy outcomes included changes in total body weight (45.8%), body mass index (39.0%), and the proportion of weight loss (28.8%).
    3 context sentences
    Summary · context
    We carried out a comprehensive scoping review of primary studies examining the use of AOMs in adult Arab populations.
    Summary · context
    Five databases (Medline, Embase, Cochrane Library, Index Medicus for the Eastern Mediterranean Region, and e-Marefa) were searched for English-language publications up to October 2024.
    Summary · context
    Glucagon-like peptide-1 receptor agonists were investigated in 72.9% of the studies, with liraglutide being the most frequently studied agent (54.2%).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneSystematic reviewOther

    In the searched scoping review of AOM studies in adult Arab populations, weight-loss-proportion outcome reporting occurred in 28.8% of studies; no liraglutide-specific efficacy estimate was stated.

    In plain wordsIn adult Arab AOM research, weight-loss-proportion outcome reporting appeared in 28.8% of studies; this was not a liraglutide efficacy estimate.

    Peptide
    Liraglutide
    Outcome
    Not applicableWeight-loss-proportion outcome reporting across AOM studies
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Whole body

    Measurements

    Studies reporting outcome
    28.8%
    review-wide AOM studies; not a patient effect

    Source sentences

    Summary
    The most commonly reported efficacy outcomes included changes in total body weight (45.8%), body mass index (39.0%), and the proportion of weight loss (28.8%).
    3 context sentences
    Summary · context
    We carried out a comprehensive scoping review of primary studies examining the use of AOMs in adult Arab populations.
    Summary · context
    Five databases (Medline, Embase, Cochrane Library, Index Medicus for the Eastern Mediterranean Region, and e-Marefa) were searched for English-language publications up to October 2024.
    Summary · context
    Glucagon-like peptide-1 receptor agonists were investigated in 72.9% of the studies, with liraglutide being the most frequently studied agent (54.2%).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In the searched review of AOM studies in adult Arab populations, gastrointestinal side effects were reported in 32.2% of patients across studies; no liraglutide-specific rate or analyzed denominator was stated.

    In plain wordsIn adult Arab AOM studies, gastrointestinal side effects were reported in 32.2% of patients across studies; no liraglutide-specific rate was reported.

    Peptide
    Liraglutide
    Outcome
    Not applicableReview-wide gastrointestinal side-effect reporting
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Measurements

    Patients with reported gastrointestinal side effects
    32.2%
    across reviewed AOM studies; native-liraglutide rate/denominator unstated

    Source sentences

    Summary
    Gastrointestinal side effects were reported in 32.2% of patients across studies.
    3 context sentences
    Summary · context
    We carried out a comprehensive scoping review of primary studies examining the use of AOMs in adult Arab populations.
    Summary · context
    Five databases (Medline, Embase, Cochrane Library, Index Medicus for the Eastern Mediterranean Region, and e-Marefa) were searched for English-language publications up to October 2024.
    Summary · context
    Glucagon-like peptide-1 receptor agonists were investigated in 72.9% of the studies, with liraglutide being the most frequently studied agent (54.2%).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.